Treatment with palbociclib led to CDK4 attenuation, inhibiting CS cell viability via CDK 4/retinoblastoma (Rb) signaling pathway regulation and highlighting the promising use of CDK4 inhibitors in CS treatment [44,58,59]. The gene discussed is CDK4; the disease is Cowden syndrome 1.